Table 1.
Statistical evaluation of malignant glioma tumor tissues, stained for PRAF2
| Tumor cells/tissue data | Patient ratio | Percentage (%) |
|---|---|---|
| Intensity | ||
| Strong | 11/12 | 91.7 |
| Moderate | 1/12 | 8.3 |
| Weak | 0/12 | 0 |
| Negative | 0/12 | 0 |
| Quantity | ||
| >75% | 12/12 | 100 |
| 75–25% | 0/12 | 0 |
| <25% | 0/12 | 0 |
| Rare | 0/12 | 0 |
| Localization | ||
| Nuclear | 0/12 | 0 |
| Cytoplasm/Memb | 12/12 | 100 |
| Gender | ||
| Male | 9/12 | 75 |
| Female | 3/12 | 25 |
| Age | ||
| >60 years | 4/12 | 33.3 |
| >25, <60 years | 7/12 | 58.3 |
| <25 years | 1/12 | 8.4 |
| Cell type | ||
| Astrocytoma | 3/12 | 25 |
| Oligoastrocytoma | 1/12 | 8.3 |
| Oligodendroglioma | 3/12 | 25 |
| Glioblastoma | 5/12 | 41.7 |
PRAF2, prenylated Rab acceptor 1 domain family, member 2.